Thu 6/4/2020 11:04 ET
DJIA26356.7086.980.33%TELCO172.320.050.03%GOLD1731.6018.351.06%Shanghai2919.254.090.14%
S&P 5003124.671.870.06%BANKS372.458.832.37%OIL35.341.634.61%BITCOIN9746.9893.570.96%
NASDAQ9687.704.840.05%PHARM609.794.330.71%US/EU1.130.011.01%Futures3057.2519.260.63%
Welcome Stranger!  Please sign up or log in to enable additional features.Sign Up | Mail | Log In
Forum - NeuroBo Pharmaceuticals - NRBO   

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add NRBO
  
From: efbailey (Rep: 1765) reply to SunTzu772Date: 04/07/2020 20:10
Forum: NeuroBo Pharmaceuticals - Msg #72Thread #674132695 (Rec: 0)
Re:gotta love the stealth move here, volume day like 2/12 prob sees $50

7.95 8.03 adds..19.00..210K float still 19% short..one week now..NB-01



Reply to SunTzu772 - Msg #71 - 04/06/2020 10:09

Re: 7.95 8.03 adds..19.00..210K float still 19% short..one week now..NB-01

Overview of Current Clinical Pipeline

NB-01 – addresses a range of mechanisms that contribute to neuropathic pain and nerve degeneration in diabetic and other peripheral neuropathies. These include a decrease in key inflammatory markers, restoration of nerve growth factor (NGF) to normal levels, and reduction of advanced glycation end products (AGEs). NB-01 also reduces levels of TNF- and IL-6, both of which are markers of inflammation, which are implicated in diabetes-related complications. NB-01 also restores the neurotrophin NGF, which is involved in nerve growth, maintenance and repair.

NB-01 was developed primarily as a treatment for painful diabetic neuropathy (PDN), but NB-01 can also treat other neuropathic pain conditions, including chemotherapy-induced peripheral neuropathy and post-traumatic peripheral neuropathy. The global neuropathic pain market is currently estimated to be greater than $5 billion and is projected to grow to more than $10 billion by 2026. In the United States, there are currently only three FDA-approved treatments for PDN.

The company believes that NB-01 has the potential to offer pain alleviation with minimal side effects and to be potentially the first disease-modifying therapy impacting the underlying disease mechanisms. NB-01 has successfully completed two Phase 2 proof-of-concept clinical trials for PDN.

In addition to the pharmaceutical market to treat pain, there is a very large and growing market for nutraceuticals in this arena. Since NB-01 is derived from natural products, the company is considering marketing NB-01 as a nutraceutical (non-pharmaceutical) product.

·

NB-02 - has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of a protein called tau, and with amyloid beta plaque deposition. NB-02 has shown considerable promise as a neuroprotective agent in preclinical studies, demonstrating a multimodal mechanism of action including inhibition of tau phosphorylation, acetylcholinesterase (AChE) inhibition, inhibition of A toxicity and amyloid plaque formation, and anti-inflammatory effects. The company intends to further leverage the benefits of tau modulation by NB-02 in conjunction with the other pathway effects to explore treatment of certain dementias such as the tauopathies.

The company believes that leveraging the therapeutic advantages of NB-02 will drive a paradigm shift in the treatment of Alzheimer’s disease and other neurodegenerative diseases. The company also is assessing whether to pursue further development of NB-02 as an orphan drug.

·

Gemcabene – is a novel, once-daily, oral therapy designed to target known lipid metabolic pathways to lower levels of LDL-C, hsCRP and triglycerides, that originally was licensed from Pfizer. It is in development for the treatment of dyslipidemia, a serious medical condition that increases the risk of life-threatening cardiovascular disease, focused on orphan indications such as homozygous familial hypercholesterolemia (HoFH), as well as severe hypertriglyceridemia (SHTG). Gemcabene has been tested as a monotherapy and in combination with statins and other drugs in more than 1,100 subjects across 25 Phase 1 and Phase 2 clinical trials and has demonstrated promising evidence of efficacy, safety and tolerability.

In August 2018, Gemphire announced that the FDA, following submission of its two-year rodent carcinogenicity study, had requested additional preclinical studies, including a 13-week PPAR knockout mouse study. The in vitro PPAR transactivation studies and subchronic study of Gemcabene in PPAR knock-out mice are completed, and the company is expecting to receive a response from the FDA in the second quarter of 2020 regarding removal of the partial clinical hold.

https://www.sec.gov/Archives/edgar/data/1638287/000155837020003388/ex-99d1.htm
What would you like to do? Message: Endorse | Bookmark | Report AbuseUser efbailey: Reward | Watch | IgnoreNRBO: Ignore

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add NRBO
  

TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.